Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

The Costa Rica HPV16/18 Vaccine Trial (CVT) showed that four-year vaccine efficacy against 12-month HPV16/18 persistent infection was similarly high among women who received one, two, or the recommended three doses of the bivalent HPV16/18 L1 virus-like particle (VLP) vaccine. Live-attenuated viral...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Prev Res (Phila)
Main Authors: Safaeian, Mahboobeh, Porras, Carolina, Pan, Yuanji, Kreimer, Aimee, Schiller, John T., Gonzalez, Paula, Lowy, Douglas R., Wacholder, Sholom, Schiffman, Mark, Rodriguez, Ana C., Herrero, Rolando, Kemp, Troy, Shelton, Gloriana, Quint, Wim, van Doorn, Leen-Jan, Hildesheim, Allan, Pinto, Ligia A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7605443/
https://ncbi.nlm.nih.gov/pubmed/24189371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-13-0203
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados